Intracellular apoptotic pathways: a potential target for reducing joint damage in rheumatoid arthritis

Inflamm Res. 2018 Mar;67(3):219-231. doi: 10.1007/s00011-017-1116-5. Epub 2017 Nov 21.

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that results in both local and systemic bone erosion, causing significant joint deformities and functional disability. The increased number of synovial fibroblasts, inflammatory cells and osteoclasts in RA is associated with reduced apoptosis in these cells. The ability to modulate the cell proliferation or death (particularly apoptosis) is recognised for its immense therapeutic potential. Identifying new therapeutics to assist in stimulating apoptosis within the synovial joints therefore may be beneficial in reducing inflammation and bone loss in RA patients. In this review, the roles of anti-apoptotic proteins that are upregulated in RA synovial joints will be discussed in relation to their actions on bone destruction and inflammation. Evidence recently published suggests that intracellular apoptotic inhibitory molecules can be targeted by current or new therapeutics to reduce joint damage in RA. However, the therapeutics that target these molecules are yet to reach clinical trial stages. Even so it is evident that understanding the upregulation of anti-apoptotic molecules in RA is required to improve treatments currently available for RA patients.

Keywords: Anti-apoptotic proteins; Apoptosis; Bone erosion; Disease-modifying anti-rheumatic drugs; Rheumatoid arthritis; Therapeutics.

Publication types

  • Review

MeSH terms

  • Animals
  • Apoptosis* / physiology
  • Arthritis, Rheumatoid / metabolism*
  • Humans
  • Signal Transduction